Immunochina Pharmaceuticals, a Beijing‑based biotech, announced that its first fully in‑house developed, CD19‑targeted autologous CAR‑T cell therapy, IM19 CAR‑T Cell (development code: IM19), has been approved for marketing by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory large B‑cell lymphoma (r/r LBCL) who have received two or more lines of systemic therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Marketing approval |
| Product | IM19 CAR‑T Cell (development code: IM19) |
| Modality | CD19‑targeted autologous CAR‑T cell therapy |
| Indication | Adult patients with relapsed or refractory large B‑cell lymphoma who have received two or more lines of systemic therapy |
| Approval Date | 5 Nov 2026 |
| Distinction | Immunochina’s first fully in‑house developed CAR‑T therapy approved for marketing |
Product Profile & Molecular Design
- End‑to‑End Independence: IM19 was independently developed through a one‑stop, fully in‑house model, ensuring independence and controllability across R&D, manufacturing, and quality management — a vertically integrated approach spanning the entire CAR‑T value chain.
- Proprietary Protective Peptide: An innovative molecular design incorporates a proprietary protective peptide structure in the CAR antigen‑recognition domain, which stabilizes molecular conformation, improves CD19 recognition efficiency, and enhances tumor‑specific killing capability at the source.
- 4‑1BB Co‑Stimulatory Domain: The construct uses a 4‑1BB co‑stimulatory domain to promote longer‑term in vivo CAR‑T cell expansion and sustained anti‑tumor responses, while reducing pro‑inflammatory cytokine release to lower the risk of immunotoxicity.
- Low Immunogenicity: The protective peptide structure also effectively reduces the immunogenicity of the CAR molecule, yielding an anti‑drug antibody (ADA) positivity rate of just 6.4 % in confirmatory clinical trials.
- Durability Foundation: Reduced immunogenicity significantly extends CAR‑T persistence in patients, establishing a foundation for long‑term, sustained tumor control.
Clinical & Engineering Evidence
| Design Feature | Functional Benefit | Supporting Data |
|---|---|---|
| Protective peptide in antigen‑recognition domain | Stabilized conformation; improved CD19 recognition; enhanced tumor‑specific killing | ADA positivity rate of 6.4 % in confirmatory clinical trials |
| 4‑1BB co‑stimulatory domain | Longer‑term in vivo expansion; sustained anti‑tumor response | Reduced pro‑inflammatory cytokine release; lower immunotoxicity risk |
| Reduced CAR immunogenicity | Extended CAR‑T persistence | Foundation for long‑term, sustained tumor control |
Confirmatory clinical trial efficacy endpoints (such as response rate and survival outcomes) were not disclosed in the announcement.
Market Impact & Outlook
- Aggressive Disease, High Unmet Need: Relapsed or refractory large B‑cell lymphoma after two or more lines of systemic therapy remains one of the most challenging settings in hematologic oncology, where CAR‑T cell therapy has become a transformative treatment class.
- Vertical Integration Advantage: Full in‑house control of R&D, manufacturing, and quality management is strategically critical for autologous cell therapies, where supply‑chain reliability and batch consistency directly determine commercial viability and patient access.
- Differentiated Engineering: The combination of a protective peptide design and 4‑1BB co‑stimulation targets two persistent challenges in CAR‑T therapy — immunogenicity‑driven loss of persistence and cytokine‑mediated toxicity — potentially improving the benefit‑risk profile versus earlier‑generation constructs.
- Growing China CAR‑T Landscape: IM19 joins an expanding roster of NMPA‑approved CD19 CAR‑T therapies in China, adding domestic competition to a market that continues to mature in both clinical adoption and manufacturing capability.
- Next Catalysts: Commercial launch and treatment‑center activation, real‑world persistence and durability data, and potential expansion into additional B‑cell malignancy indications.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercialization, clinical performance in real‑world use, and potential indication expansion for IM19 CAR‑T Cell. Actual results may differ due to risks including manufacturing scale‑up and supply execution, market adoption, reimbursement and access dynamics, competitive pressures, and post‑marketing safety findings.-Fineline Info & Tech
